Adaptimmune Therapeutics plc (ADAP)
Upgrades & Downgrades
Latest ADAP news
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcri...
6 August 2022
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Off...
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
1 July 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
29 June 2022
SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the trea...
Why Adaptimmune Therapeutics Stock Is Popping Today
27 June 2022
Buyout fever is sparking interest in the biotech's beaten-down shares today.
Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
19 June 2022
Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell...
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
17 May 2022
The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.
Adaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call Transcript
9 May 2022
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Office...
New Strong Sell Stocks for April 26th
26 April 2022
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
New Strong Sell Stocks for April 22nd
22 April 2022
BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022